Hydroxychloroquine does not prevent the spread of COVID


It also does not appear to improve symptoms.

A clinical study conducted by epidemiologists Oriol Mitzja and Bonaventura Clotet showed that hydroxychloroquine (HCQ) does not prevent spread coronavirus in healthy people who have been infected with a positive case and does not help improve the symptoms of the disease.

A study published Tuesday in the New England Journal of Medicine notes that Ihydroxychloroquine does not affect the development of covid-19 in healthy people a positive case was identified using a PCR test and does not affect the improvement of symptoms of infection.

To come to this conclusion researchers administered the drug for seven days people who had previously been exposed to the virus, which allowed them to be advised to stop post-exposure prophylaxis with HCQ.

The trial was conducted in Catalonia from March 17 to April 28, 2020, during the first wave of the COVID-19 pandemic, and consisted of a Phase 3 randomized trial conducted among the population of central Catalonia, the metropolitan region. north and the city of Barcelona, ​​a total of 2,314 involved contacts out of 672 positive cases.

All participants were adults and had to be in close contact, less than two meters, with an infected person for at least 15 minutes and for seven days prior to recruitment.

Exclusion criteria: Symptoms of COVID-19 at the time of registration., are taking medications contraindicated for the use of hydroxychloroquine, have a history of cardiac arrhythmias, renal failure, are pregnant or breastfeeding.

Participants were randomized so that one group was given 800 mg of hydroxychloroquine on day 1 followed by a daily dose of 400 mg, while the other group received no treatment.

At the same time, they received their first personal visit to the doctor, during which health questionnaires and structured interviews were conducted, physical examination and collection of nasopharyngeal PCR samples for analysis in the laboratory, and clinical observation was carried out on days 3 and 7. monitor phone calls.

If the participant developed Covid-19 symptoms during treatment or within seven days, the field team also visited him for a new medical examination and a new collection of nasopharyngeal samples using PCR.

On the 14th day of the study contacts who did not get COVID-19 visited at home take a PCR test and a serological test.

Research has shown that The incidence and progression of the disease in participating contacts are similar between patients in the treatment group (5.7%) and in the control group (6.2%).

The transmission rate, measured by PCR, showed the same trend: 18.7% in the experimental group versus 17.8% in the control group.

As for the side effects, 5.6% of patients in the treatment group experienced at least one during the 14-day follow-up period., the vast majority of these are mild in nature, but in six patients, the researchers observed up to five episodes of heartbeat, potentially related to treatment, and one episode caused by respiratory failure.

21 Catalan institutions have participated in the project, including the Department of Health, Aquas, Ceeiscat, Hospital Germans Trias i Pujol, Hospital Bellvitge, Hospital de Mataró, Primary Health Care Teams of Central Catalonia, Metropolitana Nord, Barcelona. , Tarragona and the EAP Sarrià and EBA Centelles teams as well as the NGO Open Arms.

To fund it, the organization received the support of more than 72,000 people and organizations who donated funds through the #YoMeCorono campaign launched on March 18 to conduct this and other investigations aimed at being able to confront the pandemic.

Be the first to comment

Leave a Reply

Your email address will not be published.